NS
NSTM.US Hollywood Media Co
- Market cap
- USD 493K
- P/E
- -
- P/B
- 0.51x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is NSTM.US undervalued?
Graham numberThe Graham number of Hollywood Media Co cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hollywood Media Co fundamental analysis
No fundamental analysis for Hollywood Media Co yet.
Hollywood Media Co stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hollywood Media Co
NovelStem International Corp., a development stage biotechnology holding company, focuses on development and commercialization of diagnostic technology for cancer treatments and to reduce resistance to chemotherapy. The company was formerly known as Hollywood Media Corp. and changed its name to NovelStem International Corp. in September 2018. NovelStem International Corp. was incorporated in 1993 and is headquartered in Boca Raton, Florida.
Full company profileHollywood Media Co financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hollywood Media Co annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2010 | 2011 | 2012 | 2013 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 4.00M | 3.77M | 616K | 425K | - | 0.00 | 12.0K | 12.0K | 12.0K | 0.00 | 0.00 |
| Gross Profit | -1.35M | -336K | 613K | -1.70M | - | - | 12.0K | 12.0K | 12.0K | - | - |
| Operating Income | -7.66M | -5.81M | -5.70M | -4.89M | -230K | -496K | -422K | -3.53M | -928K | -239K | -79.8K |
| EBITDA | -7.12M | -5.61M | -5.57M | 6.53M | 295.00 | -496K | -422K | -3.13M | -1.78M | -239K | -79.8K |
| Net Income | 4.91M | -6.86M | 10.4M | 6.25M | -545K | -1.35M | -766K | -4.19M | -3.23M | 2.38M | -282K |
| EPS | 0.16 | -0.28 | 0.45 | 0.28 | -0.01 | -0.03 | -0.02 | -0.09 | -0.07 | 0.05 | -0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 47.3M | 18.2M | 26.6M | 31.5M | 3.56M | 2.61M | 2.29M | 2.25M | 160K | 15.8K | 15.8K |
| Total Liabilities | 9.57M | 3.65M | 1.66M | 1.40M | 68.7K | 193K | 353K | 4.21M | 5.30M | 2.16M | 2.16M |
| Shareholders' Equity | 37.8M | 14.6M | 25.0M | 30.1M | 3.49M | 2.42M | 1.93M | -1.95M | -5.14M | -2.14M | -2.03M |
| Cash & Short-term Investments | 29.4M | 3.72M | 11.4M | 22.9M | 89.6K | 8.67K | 6.35K | 53.1K | 6.10K | 333.00 | 333.00 |
| Total Debt | 101K | 38.0K | 18.4K | 34.3K | - | 100K | 288K | 3.57M | 4.42M | 1.73M | 1.73M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 3.93M | -2.59M | -3.92M | 419K | 419K | -181K | -182K | -348K | -272K | -168K | -345K |
| Capital Expenditure | 142K | 123K | 84.0K | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 | 4.00 | 0.00 | 0.00 |
| Free Cash Flow | 3.79M | -2.72M | -4.00M | - | 419K | -181K | -182K | -348K | -272K | -168K | -345K |
| Ratios | |||||||||||
| ROE | 13.0% | -47.1% | 41.7% | 20.8% | -15.6% | -56.0% | -39.6% | - | - | - | - |
| ROA | 10.4% | -37.7% | 39.1% | 19.9% | -15.3% | -51.8% | -33.5% | -185.7% | -2,019.2% | 15,075.9% | -1,784.1% |
| Net Profit Margin | 122.8% | -182.0% | 1,689.0% | 1,472.2% | - | - | -6,381.1% | -34,891.7% | -26,941.7% | - | - |
| Debt to Equity | 0.00x | 0.00x | 0.00x | 0.00x | - | 0.04x | 0.15x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Hollywood Media Co dividends
Hollywood Media Co has not paid dividends in the last 9 fiscal years.
Who owns Hollywood Media Co
- Insiders 58.57%
- Institutions 0.05%
- Public & others 41.38%
- Shares outstanding 49.3M
- Free float 20.4M
Hollywood Media Co company profile
- Company name
- Hollywood Media Co
- Ticker
- NSTM.US
- Exchange
- USA Stocks
- Listed since
- Nov 12, 1993
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 2255 Glades Road, Boca Raton, FL, United States, 33431
- Phone
- 410 598 9024
- Website
- novelstem.com
About Hollywood Media Co
NovelStem International Corp., a development stage biotechnology holding company, focuses on development and commercialization of diagnostic technology for cancer treatments and to reduce resistance to chemotherapy. The company was formerly known as Hollywood Media Corp. and changed its name to NovelStem International Corp. in September 2018. NovelStem International Corp. was incorporated in 1993 and is headquartered in Boca Raton, Florida.
Hollywood Media Co management
4- Mr. Jan H. LoebExecutive Chairman & President · born 1959
- Mr. Mitchell Rubenstein J.D.Co-Founder & Independent Director · born 1954
- Ms. Christine T. JenkinsVP, CFO & Secretary · born 1964
- Mr. David CollinsInvestor Relations Firm, Catalyst IR